Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets
July 11, 2023Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology
Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …
MHRA authorises GSK’s RSV vaccine for older adults
July 10, 2023Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …
Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment
July 10, 2023Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix
Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …
Celltrion launches Humira biosimilar in US
July 7, 2023Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion
South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …
OSE Immunotherapies’ UC drug gets DSMB positive recommendation
July 6, 2023Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis
French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …
FDA grants Priority Review for Astellas Pharma’s BLA for cancer drug
July 6, 2023Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology
Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …
Skyline Therapeutics receives FDA clearance of IND for candidate for neovascular age-related macular degeneration
July 5, 2023Research and Development FDA, IND, Opthalmology, Skyline Therapeutics, neovascular age-related macular degeneration
Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …
Jacobio Pharma receives CDE approval for pancreatic cancer study in China
July 5, 2023Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial
Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …
Roger Dmochowski appointed as Versameb’s chief medical officer
July 5, 2023Business Services Roger Dmochowski, Urology, Versameb, appointment, chief medical officer
Versameb AB has announced the appointment of Professor Roger Dmochowski as chief medical officer. Dmochowski is a renowned researcher and …
Cytovation appoints Olav Hellebø to board of directors
July 5, 2023Business Services Cytovation, Olav Hellebø, Oncology, appointment, board of directors
Cytovation ASA, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has …
Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis
July 4, 2023Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis
A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
Croda International acquires Solus Biotech
July 4, 2023Business Services Croda International, Pharmacy, Solus Biotech, acquisition
Croda International has confirmed that it has successfully acquired Solus Biotech, following receipt of approval from the South Korean regulatory …
Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy
July 3, 2023Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia
Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …
Josef Penninger appointed as new scientific director of Helmholtz Centre for Infection Research
July 3, 2023Business Services Helmholtz Centre for Infection Research, Josef Penninger, appointment, scientific director
The Helmholtz Centre for Infection Research (HZI), Germany, has appointed Professor Josef Penninger as scientific director. Penninger has previously worked …
Kevin Hawkins appointed as Reacta’s head of regulatory affairs
July 3, 2023Business Services Kevin Hawkins, Reacta, appointment, head of regulatory affairs
Reacta Healthcare, an early-stage food allergy diagnostic company, has announced the appointment of Kevin Hawkins as head of regulatory affairs. …
FDA approves BioMarin’s Roctavian for adults with severe haemophilia A
June 30, 2023Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia
Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …
Eli Lilly to acquire Sigilon Therapeutics
June 30, 2023Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition
Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …
First cellular therapy for patients with type 1 diabetes approved by FDA
June 29, 2023Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes
The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet …
